See more : Ice Fish Farm AS (IFISH.OL) Income Statement Analysis – Financial Results
Complete financial analysis of MiNK Therapeutics, Inc. (INKT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MiNK Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fifth Third Bancorp (FITBO) Income Statement Analysis – Financial Results
- Eqonex Limited (EQOS) Income Statement Analysis – Financial Results
- Thessaloniki Water Supply & Sewerage Co S.A. (EYAPS.AT) Income Statement Analysis – Financial Results
- Walmart Inc. (WMT) Income Statement Analysis – Financial Results
- Otello Corporation ASA (OPESF) Income Statement Analysis – Financial Results
MiNK Therapeutics, Inc. (INKT)
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 2.70B | 0.00 | 0.00 | 689.63K |
| Cost of Revenue | 204.62K | 30.95B | 28.36B | 55.06K | 0.00 |
| Gross Profit | -204.62K | -28.24B | -28.36B | -55.06K | 689.63K |
| Gross Profit Ratio | 0.00% | -1,044.26% | 0.00% | 0.00% | 100.00% |
| Research & Development | 15.49M | 23.12M | 13.97M | 9.51M | 19.65M |
| General & Administrative | 7.43M | 7.83M | 4.64M | 1.29M | 3.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.43M | 7.83M | 4.64M | 1.29M | 3.83M |
| Other Expenses | 0.00 | 2.70M | -9.53M | -3.00M | 551.24K |
| Operating Expenses | 22.92M | 30.95M | 18.61M | 10.80M | 23.48M |
| Cost & Expenses | 22.92M | 30.95M | 18.61M | 10.80M | 23.48M |
| Interest Income | 463.26K | 253.32K | 2.43K | 2.44K | 1.56K |
| Interest Expense | 0.00 | 253.32K | 2.43M | 2.44M | 1.56M |
| Depreciation & Amortization | 204.62K | 121.75K | 77.96K | 55.06K | 36.82K |
| EBITDA | -22.25M | -30.83M | -27.70M | -13.74M | -22.20M |
| EBITDA Ratio | 0.00% | -1.14% | 0.00% | 0.00% | -3,219.79% |
| Operating Income | -22.92M | -30.95M | -28.36M | -14.64M | -22.28M |
| Operating Income Ratio | 0.00% | -1.14% | 0.00% | 0.00% | -3,231.39% |
| Total Other Income/Expenses | 463.25K | 2.96M | -1.85M | -1.60M | -1.52M |
| Income Before Tax | -22.46M | -27.99M | -30.21M | -16.24M | -23.80M |
| Income Before Tax Ratio | 0.00% | -1.03% | 0.00% | 0.00% | -3,451.46% |
| Income Tax Expense | 0.00 | -3.21M | -7.10M | -560.38K | 2.11M |
| Net Income | -22.46M | -24.78M | -23.11M | -15.68M | -25.91M |
| Net Income Ratio | 0.00% | -0.92% | 0.00% | 0.00% | -3,757.73% |
| EPS | -0.65 | -0.74 | -0.69 | -0.47 | -0.78 |
| EPS Diluted | -0.65 | -0.74 | -0.69 | -0.47 | -0.78 |
| Weighted Avg Shares Out | 34.36M | 33.67M | 33.48M | 33.09M | 33.09M |
| Weighted Avg Shares Out (Dil) | 34.36M | 33.67M | 33.48M | 33.09M | 33.09M |
MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Paul...
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today...
MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the...
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board...
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies and Autonomous Therapeutics, Inc. (Autonomous), a leader developing first-in-class, disease-activated RNA...
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today...
MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Zack Armen - Head, Investor Relations Jennifer Buell - President and Chief Executive Officer Marc Van Dijk - Chief Scientific Officer Christine...
MiNK Reports Second Quarter 2024 Results and Business Update
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today...
Source: https://incomestatements.info
Category: Stock Reports